Akiva Mintz
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDOPA and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.
This research study aims to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring. "Investigational" means that the procedure or drug being studied is not yet approved by the FDA for the specific use being tested in this research. The PET imaging technique used in this study is considered investigational because it is being tested at an ultralow radiation dose that has not yet been approved for clinical use. The radiotracer, 18F-FDOPA, is FDA-approved for detecting prostate cancer at standard dose…
Inclusion Criteria: 1. age ≥18 years. 2. ability to provide informed consent and comply with study procedures. 3. for female participants: * must not be pregnant or breastfeeding. * negative pregnancy test required for women of childbearing potential. Exclusion criteria: 1. participants who have exceeded Nuclear Regulatory Commission regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total). 2. more than four prior enrollments in this study. 3. participants with severe claustrophobia, chronic pain, or musculoskeletal conditions th…
Participants will be injected with 18F-FDOPA and imaged for up to 3 hours on a PET scanner
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.